Prostate Cell News Volume 4.02 | Jan 18 2013

LABORATORY RESEARCH

CCN3/NOV Gene Expression in Human Prostate Cancer Is Directly Suppressed by the Androgen Receptor
Through meta-analysis of microarray data, the authors nominate nephroblastoma overexpressed (NOV) as a top androgen-repressed gene. They show that NOV is directly suppressed by androgen through the androgen receptor. [Oncogene] Abstract

Conditionally Ablated Pten in Prostate Basal Cells Promotes Basal-to-Luminal Differentiation and Causes Invasive Prostate Cancer in Mice
Recent evidence from a prostate regeneration assay suggests that prostate basal cells give rise to prostate cancer. Here, researchers characterized Pten-deficient prostate lesions arising from keratin 5-expressing basal cells in a temporally controlled system in mice. [Am J Pathol] Abstract

Bone Marrow Mesenchymal Stem Cells Increase Motility of Prostate Cancer Cells via Production of Stromal Cell-Derived Factor-1α
To study the interaction between factors secreted by bone marrow mesenchymal stem cells (BM-MSCs) and prostate cancer cells, the authors established an in vitro model of transwell co-culture of BM-MSCs and prostate cancer cells DU145. [Cell Mol Med] Full Article

Upregulation of SATB1 Is Associated with Prostate Cancer Aggressiveness and Disease Progression
Researchers demonstrated that Special AT-rich binding protein (SATB1) plays significant role in prostate tumor invasion and migration and its nuclear localization correlates with disease aggressiveness. [PLoS One] Full Article

Prostate Cancer Stem-Like Cells/Cancer-Initiating Cells Have an Autocrine System of Hepatocyte Growth Factor
Prostate cancer stem-like/cancer-initiating cells were isolated as aldehyde dehydrogenase 1-high cells using the ALDEFLUOR assay, and the gene expression profiles were analyzed using a cDNA microarray and RT-PCR. [Cancer Sci] Abstract

Platelet-Derived Growth Factor-BB Accelerates Prostate Cancer Growth by Promoting the Proliferation of Mesenchymal Stem Cells
Investigators found that mesenchymal stem cells promoted prostate cancer (PCa) tumor growth in vivo and cell proliferation in vitro by using PCa cell strain RM-1. [J Cell Biochem] Abstract

CLINICAL RESEARCH

Androgen-Deprivation Therapy Alone or with Docetaxel in Non-Castrate Metastatic Prostate Cancer (GETUG-AFU 15): A Randomized, Open-Label, Phase III Trial
Scientists investigated the effects of the addition of docetaxel to androgen-deprivation therapy (ADT) for patients with metastatic non-castrate prostate cancer. [Lancet Oncol] Abstract

Phase II Open Label, Multi-Center Clinical Trial of Modulation of Intermediate Endpoint Biomarkers by 1α-Hydroxyvitamin D2 in Patients with Clinically Localized Prostate Cancer and High Grade PIN
The authors evaluated the biologic activity of a less calcemic vitamin D analog 1α-hydroxyvitamin D2 in patients with prostate cancer and high grade prostatic intraepithelial neoplasia (PIN). [Prostate] Abstract

Changes in Serum Prostate-Specific Antigen Levels and the Identification of Prostate Cancer in a Large Managed Care Population
Given the questions that remain regarding the use of the rate of change in prostate-specific antigen as a screening tool for prostate cancer because of previous conflicting studies, which to date have included small, highly selected populations, researchers add to the existing knowledge by assessing this question in general practice settings among a large, diverse population. [BJU Int]
Abstract | Press Release | Video Press Release

Project to Capture, Interrogate Single Cancer Cells Wins Innovator Award
From a single cell gone bad, cancer evolves into an increasingly complex tumor built of a variety of normal cells and diverse malignant cells, some of which escape to create dangerous colonies in other organs, further jumbling the treatment picture. Nicholas Navin, Ph.D. believes the key to sorting out this cellular chaos is by identifying important mutations in single tumor cells at various stages of the cancer’s development. The Damon Runyon Cancer Research Foundation wants Navin to test his idea, naming him the Nadia’s Gift Foundation Innovator, providing $150,000 a year for three years. [The University of Texas MD Anderson Cancer Center] Press Release | Video

Scientists Seek Out Cancer Cells Hiding from Treatment
Researchers will begin a three year project to explore how some cancer cells evade treatment, thanks to new funding from blood cancer charity Leukemia & Lymphoma Research. [Imperial College London]
Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Cold Spring Harbor Laboratory – Cancer Biology & Therapeutics
April 23-27, 2013
Cold Spring Harbor, United States

Visit our events page to see a complete list of events in the prostate cell community.

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

Postdoctoral Position – Convergence of the ZMIZ1 and NOTCH1 Pathways at C-MYC in Acute T Lymphoblastic Leukemias (University of Michigan – Ann Arbor)

Postdoctoral Position – Androgen Receptor Genomics (The Netherlands Cancer Institute)

Associate Professor – Urologic Cancers (Oregon Health & Science University [OHSU])

Assistant, Associate or Full Professor – Cancer Early Detection (Stanford University School of Medicine)

Postdoctoral Position – Prostate Cancer Theranostics (The University of Queensland)

Recruit Top Talent : Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.